Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | ACACB | O00763 | 3/20 | 0.46 |
| ▸ | MCHR2 | Q969V1 | 2/20 | 0.45 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4988665 | 0.79 | AVPR1A (0.58) | HSD11B1ACACB | |
| SCHEMBL3840707 | 0.73 | HSD11B1 (0.57) | HSD11B1MCHR2NPC1L1 | |
| SCHEMBL4363635 | 0.73 | AVPR1A (0.64) | HSD11B1MCHR2 | |
| SCHEMBL3837633 | 0.71 | MCHR2 (0.60) | HSD11B1MCHR2NPC1L1 | |
| SCHEMBL3840249 | 0.70 | ACACB (0.47) | ACACB | |
| SCHEMBL395086 | 0.70 | HSD11B1 (0.64) | HSD11B1MCHR2NPC1L1 | |
| SCHEMBL3839355 | 0.69 | MCHR2 (0.61) | HSD11B1MCHR2NPC1L1 | |
| SCHEMBL2211646 | 0.67 | HRH4 (0.58) | HSD11B1MCHR2NPC1L1 | |
| SCHEMBL738652 | 0.65 | MCHR2 (0.54) | HSD11B1ACACBMCHR2NPC1L1 | |
| SCHEMBL4363935 | 0.65 | MEN1 (0.63) | HSD11B1MCHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153863-A1 | SPIROPIPERIDINE DERIVATIVES | HOFFMAN-LA ROCHE INC. | 2008-06-26 | — | — | US | claimed |
| EP-2535329-A2 | Spiro-piperidine derivatives | F. Hoffmann-La Roche AG (CH) | 2012-12-19 | — | — | EP | disclosed |
| EP-2535329-A2 | Spiro-piperidine derivatives | F. Hoffmann-La Roche AG (CH) | 2012-12-19 | — | — | EP | disclosed |
| US-8084609-B2 | Vasopressin receptor (V1a) antagonists, treatment of anxiety and depressive disorders and other diseases | HOFFMAN-LA ROCHE INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084609-B2 | Vasopressin receptor (V1a) antagonists, treatment of anxiety and depressive disorders and other diseases | HOFFMAN-LA ROCHE INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084609-B2 | Vasopressin receptor (V1a) antagonists, treatment of anxiety and depressive disorders and other diseases | HOFFMAN-LA ROCHE INC. (US) | 2011-12-27 | — | — | US | disclosed |
| EP-2097376-A2 | SPIRO-PIPERIDINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008077810-A2 | SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008077810-A2 | SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| US-20080153861-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153861-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153861-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153862-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153862-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153862-A1 | SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080153863-A1 | SPIROPIPERIDINE DERIVATIVES | HOFFMAN-LA ROCHE INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153863-A1 | SPIROPIPERIDINE DERIVATIVES | HOFFMAN-LA ROCHE INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153863-A1 | SPIROPIPERIDINE DERIVATIVES | HOFFMAN-LA ROCHE INC. | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153863-A1 | SPIROPIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | HSD11B1 1341/4885ACACB 4787/4885MCHR2 325/4885 |
| US-20080153861-A1 | SPIROPIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | HSD11B1 1341/4885ACACB 4787/4885MCHR2 325/4885 |
| US-20080153862-A1 | SPIROPIPERIDINE DERIVATIVES | AVPR1A, AVPR1B, AVPR2 | HSD11B1 1341/4885ACACB 4787/4885MCHR2 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.